Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 1
2013 3
2014 5
2015 1
2016 3
2017 2
2018 1
2019 1
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

17 results
Results by year
Filters applied: . Clear all
Page 1
Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial.
Witzel I, Loibl S, Wirtz R, Fasching PA, Denkert C, Weber K, Lück HJ, Huober J, Karn T, Mackelenbergh MV, Marmé F, Schem C, Stickeler E, Untch M, Müller V. Witzel I, et al. Br J Cancer. 2019 Dec;121(12):1009-1015. doi: 10.1038/s41416-019-0630-3. Epub 2019 Nov 15. Br J Cancer. 2019. PMID: 31728025
Body Mass Index Influences the Prognostic Impact of Combined Nuclear Insulin Receptor and Estrogen Receptor Expression in Primary Breast Cancer.
Björner S, Rosendahl AH, Simonsson M, Markkula A, Jirström K, Borgquist S, Rose C, Ingvar C, Jernström H. Björner S, et al. Front Endocrinol (Lausanne). 2017 Nov 28;8:332. doi: 10.3389/fendo.2017.00332. eCollection 2017. Front Endocrinol (Lausanne). 2017. PMID: 29234306 Free PMC article.
Combined and individual tumor-specific expression of insulin-like growth factor-I receptor, insulin receptor and phospho-insulin-like growth factor-I receptor/insulin receptor in primary breast cancer: Implications for prognosis in different treatment groups.
Björner S, Rosendahl AH, Simonsson M, Markkula A, Jirström K, Borgquist S, Rose C, Ingvar C, Jernström H. Björner S, et al. Oncotarget. 2017 Feb 7;8(6):9093-9107. doi: 10.18632/oncotarget.14082. Oncotarget. 2017. PMID: 28030849 Free PMC article.
17 results
Jump to page
Feedback